Effect of Bromocriptine on Insulin Resistance in Patients with PCO


Introduction: Poly cystic ovary (PCO) is one of the most common endocrine disorders in women. All patients with PCO are at risk of insulin resistance, IFG and diabetes. Recently, bromocriptine is used in treatment of diabetes mellitus type II to improve insulin resistance. Objective: The aim of this study is the evaluation of bromocriptine on insulin resistance in PCO people. Patients and Methods: In this single-blind controlled clinical trial with placebo, 44 patients with PCO referring to endocrinology clinic were evaluated. Inclusion criteria were BMI > 25 kg/m2 and diagnosed PCO patients according to Rotterdam criteria and rule out other causes. Blood samples were obtained for FBS, Fasting Insulin, Prolactin, TSH and 17(OH)P. They divided two groups: Case group was given bromocriptine 2.5 mg daily and placebo was given to control group. Patients were treated for 8 days and in day 9th blood sample was obtained for FBS, Fasting insulin, HOMA-IR index. Mann-Whitney method is used for mean comparison. Results: Data analysis using showed in pre diabetes range, mean changes of FBS, insulin level and IR in Groups 1 and 2 had significant differences(P = 0.004), but no significant different was found in FBS < 100 mg/dl (P = 0.92). In group with BMI < 30 kg/m2, no significant differences were found in changes in FBS < insulin level and IR (P = 0.13, 0.13, and 0.11 respectively). In group with BMI ≥ 30 kg/m2, no significant differences were found in changes in insulin level and IR (P = 0.69, 0.089 respectively). Mean systolic blood pressure changes in Group 1 and 2 in FBS > 100 mg/dl with (P = 0.036) were significant, but no significant difference showed in mean change of diastolic blood pressure in FBS > 100 mg/dl (P = 0.99). In FBS < 100 mg/dl mean changes in systolic and diastolic blood pressures were not significant (P = 0.6). Age showed no difference changes in effect on treatment in Groups 1 and 2 (P = 0.1). Conclusion: Our study showed, even in the short-term consumption, bromocriptine reduced FBS and insulin levels and insulin resistance in PCO patients with pre-diabetes range.

Share and Cite:

Shirinpour, Z. , Ghaderian, B. , Rashidi, H. , Aleali, A. and Payami, S. (2014) Effect of Bromocriptine on Insulin Resistance in Patients with PCO. Open Journal of Endocrine and Metabolic Diseases, 4, 253-257. doi: 10.4236/ojemd.2014.412026.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hull, M.G.R. (1987) Epidemiology of Infertility and Polycystic Ovarian Disease: Endocrinological and Demographic Studies. Gynecological Endocrinology, 1, 235-245. http://dx.doi.org/10.3109/ 09513598709023610
[2] Dunaif, A. (1997) Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implication for Pathogenesis. Endocrine Reviews, 18, 774-800.
[3] Naderi, T., Akbarzadeh, M., Dabbaghmanesh, M.H. and Tabatabaei, H.R. (2012) Prevalence of Various Phenotypes of Polycystic Ovarian Syndrome among High School Girls of Shiraz (2009). The Journal of Qazvin University of Medical Sciences, 15, 60-67. (In Persian)
[4] Shivaprasad, C. and Kalra, S. (2011) Bromocriptin in Type 2 Diabetes Mellitus. Indian Journal of Endocrinology and Metabolism, 15, S17-S24.
[5] Ehrmann, D.A., Liljenquist, D.R., Kasza, K., Azziz, R., Legro, R.S., Ghazzi, M.N., and for the PCOS/Troglitazone Study Group (2006) Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 91, 48-53. http://dx.doi.org/10.1210/jc.2005-1329
[6] Ovalle, F. and Azziz, R. (2002) Insulin Resistance, Polycystic Ovary Syndrome, and Type 2 Diabetes Mellitus. Fertility and Sterility, 77, 1095-1105. http://dx.doi.org/10.1016/S0015-0282(02)03111-4
[7] Petersen, K.F. and Shulman, G.I. (2006) Etiology of Insulin Resistance. The American Journal of Medicine, 119, S10-S16. http://dx.doi.org/10.1016/j.amjmed.2006.01.009
[8] Legro, R.S., Castracane, V.D. and Kauffman, R.P. (2004) Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls. Obstetrical & Gynecological Survey, 59, 141-154. http://dx.doi.org/10.1097/01.OGX.0000109523.25076.E2
[9] Defronzo, R.A. (2011) Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. Diabetes Care, 34, 789-794. http://dx.doi.org/10.2337/dc11-0064
[10] Kok, P., Roelfsema, F., Frolich, M., Van Pelt, J., Stokkel, M.P., Meinders, A.E. and Pijl, H. (2006) Activation of Dopamine D2 Receptors Simultaneously Ameliorates Various Metabolic Features of Obese Women. American Journal of Physiology—Endocrinology and Metabolism, 291, E1038-E1043. http://dx.doi.org/10.1152/ajpendo.00567.2005
[11] Dos Santos Silva, C.M., Barbosa, F.R., Lima, G.A., Warszawski, L., Fontes, R., Domingues, R.C. and Gadelha, M.R. (2011) BMI and Metabolic Profile in Patients with Prolactinoma before and after Treatment with Dopamine Agonists. Obesity (Silver Spring), 19, 800-805. http://dx.doi.org/10.1038/oby.2010.150
[12] Davis, L.M., Michaelides, M., Cheskin, L.J., Moran, T.H., Aja, S., Watkins, P.A., et al. (2009) Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity. Neuroendocrinology, 89, 152-162. http://dx.doi.org/10.1159/000170586
[13] Lin, J., Lin, G.N., Pan, J.Q., Kuang, S.S., Huang, X., Rao, Z.L., et al. (2010) Studies of Bromocriptine on Insulin Resistance and Oxidative Stress in Rats with Polycystic Ovary Syndrome and Metabolic Syndrome. Clinical Medicine & Engineering, 12, 1-6.
[14] Bahceci, M., Tuzcu, A., Bahceci, S. and Tuzcu, S. (2003) Is Hyperprolactinemia Associated with Insulin Resistance in Non-Obese Patients with Polycystic Ovary Syndrome? Journal of Endocrinological Investigation, 26, 655-659.
[15] Pasquali, R., Casimirri, F., Venturoli, S., Paradisi, R., Mattioli, L., Capelli, M., Melchionda, N. and Labò, G. (1983) Insulin Resistance in Patients with Polycystic Ovaries: Its Relationship to Body Weight and Androgen Levels. Acta Endocrinologica (Copenhagen), 104, 110-116.
[16] Holt, R.I., Barnett, A.H. and Bailey, C.J. (2010) Bromocriptine: Old Drug, New Formulation and New Indication. Diabetes, Obesity and Metabolism, 12, 1048-1057. http://dx.doi.org/10.1111/j.1463-1326.2010.01304.x

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.